Heerspink HJ, Karasik A, Thuresson M et al (2020) Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
Key Products: Pemvidutide, balanced 1:1 dual GLP-1/glucagon receptor agonist, designed to drive both appetite suppression (GLP-1) and direct hepatic fat oxidation (glucagon)
Phase II, Dose-Ranging Trial A phase II, randomized, dose-finding trial of oral semaglutide was published in late 2017
The enhanced NAD+ availability and improved mitochondrial function in muscle cells may actually support muscle preservation and recovery, particularly when combined with resistance training and adequate protein intake
While vital for glucose control, insulin is also a potent growth factor that can "fuel" the proliferation and survival of cancer cells
MOTS-c affects mitochondrial function and metabolism differently than AOD 9604